Calgary, AB – April 3, 2025 – Universal Ibogaine Inc. (TSXV:IBO) (“UI” or the “Company”), a life sciences company with a mission to deliver medicalized ibogaine-centered addiction care, advises that it has agreed to settle a portion, totalling $106,200, of arrears consulting fees owed to its CEO, Nicholas Karos (the “Debt”).  UI is in process of applying to the TSX [...]

Calgary, AB – February 5, 2025 – Universal Ibogaine Inc. (TSXV:IBO) (“UI” or the “Company”), a life sciences company with a mission to deliver medicalized ibogaine-centered addiction care, provides the following update related to the previously issued Management Cease Trade Order (“MCTO”). As was noted in the Company’s prior news releases (last dated January 27, 2025), UI was not in [...]

Calgary, AB – January 27, 2025 – Universal Ibogaine Inc. (TSXV:IBO) (“UI” or the “Company”), a life sciences company with a mission to deliver medicalized ibogaine-centered addiction care, provides the following bi-weekly default status report update: Management Cease Trade Order (“MCTO”) Further to the Company’s prior news releases (dated November 18, November 26, December 11, and December 27, 2024 and [...]

Calgary, AB – January 22, 2025 – Universal Ibogaine Inc. (TSXV:IBO) (“UI” or the “Company”), a life sciences company with a mission to deliver medicalized ibogaine-centered addiction care, is pleased to advise it has closed the sale of its Belize Property. As previously announced (see prior News Releases dated November 26, December 11, and December 27, 2024 and January 13, [...]

Calgary, AB – January 13, 2025 – Universal Ibogaine Inc. (TSXV:IBO) (“UI” or the “Company”), a life sciences company with a mission to deliver medicalized ibogaine-centered addiction care, provides the following bi-weekly default status report update: Management Cease Trade Order (“MCTO”) Further to the Company’s prior news releases (dated November 18, November 26, December 11 and December 27, 2024), the [...]

Calgary, AB – December 27, 2024 – Universal Ibogaine Inc. (TSXV:IBO) (“UI” or the “Company”), a life sciences company with a mission to deliver medicalized ibogaine-centered addiction care, provides the following bi-weekly default status report update. Management Cease Trade Order (“MCTO”) Further to the Company’s prior news releases (November 18, 26 and December 11, 2024), the Company is providing this [...]

Calgary, AB – TheNewswire - December 11, 2024 – Universal Ibogaine Inc. (TSXV:IBO) (“UI” or the “Company”), a life sciences company with a mission to deliver medicalized ibogaine-centered addiction care, provides the following bi-weekly default status report update: Management Cease Trade Order (“MCTO”) Further to the Company’s prior news releases (November 18 and November 26, 2024), the Company is providing this bi-weekly default status report (the “Default [...]

Calgary, AB – TheNewswire - November 26, 2024 – Universal Ibogaine Inc. (TSXV:IBO) (“UI” or the “Company”), a life sciences company with a mission to research and deliver medicalized ibogaine-centered addiction care, is pleased to advise that it has received an offer to purchase (the “Offer”) its undeveloped 20-acre island property in Belize (the “Property”) for USD 300,000. The Offer is to [...]

Calgary, AB – November 18, 2024 – TheNewswire – Universal Ibogaine Inc. (TSXV:IBO) (“UI” or the “Company”), a life sciences company with a mission to deliver medicalized ibogaine-centered addiction care, advises that it has made an application to the Alberta Securities Commission (as Principal Regulator) and the British Columbia Securities Commission, to approve a temporary management case trade order (“MCTO”) under National [...]

Calgary, AB – June 17, 2024 – TheNewswire – Universal Ibogaine Inc. (TSXV:IBO) (“UI” or the “Company”), a life sciences company with a mission to research and deliver medicalized ibogaine-centered addiction care, advises that it has reached an agreement to issue a total of 4,040,067 common shares at a price of $0.015 per share pursuant to a settlement of accounts payable of [...]